Company Overview
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.23.
Recent Developments
- Dec 2025 Revenue of $35.95M (+1.0% YoY); net profit $-104.99M.
- Trailing 12 Months Year-on-year growth — revenue +2.8%.
- 5-Year Trend Long-term compounding — revenue CAGR -5.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -5.87% |
| 1 Year: | 2.80% |
Stock Price Performance
| 1 Year: | +52.36% |
| 6 Months: | -1.11% |
| 3 Months: | -1.11% |
| 1 Month: | -4.83% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)38.85 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -5.9% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CCCC C4 Therapeutics, Inc. PHARMA | 3.55 | -3.90 | $436.74M | 0.00% | -35.34% | -48.14% | -5.87% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 9.78M | 8.50M | 7.65M | 13.83M | 6.75M | 3.76M | 2.66M | 11.07M | 3.04M | 12.01M | 15.36M | 7.24M | 6.46M | 11.23M | 6.15M |
| Operating Income | -10.00M | -12.34M | -10.86M | -18.35M | -20.51M | -22.12M | -24.25M | -31.37M | -27.38M | -32.49M | -36.23M | -37.57M | -27.81M | -32.22M | -21.44M | -28.24M | -29.16M | -28.50M | -34.41M | -27.79M |
| Net Income | -10.09M | -11.91M | -10.79M | -21.84M | -20.97M | -22.58M | -24.68M | -31.62M | -27.41M | -31.96M | -34.78M | -35.92M | -27.04M | -28.36M | -17.72M | -24.67M | -26.32M | -26.02M | -32.17M | -25.13M |
| Diluted EPS | - | - | - | - | - | -0.51 | -0.51 | -0.65 | -0.56 | -0.65 | -0.71 | -0.73 | -0.55 | -0.41 | -0.26 | -0.35 | -0.37 | -0.37 | -0.44 | -0.20 |
| R&D Expense | 12.95M | 16.31M | 17.76M | 23.93M | 20.53M | 23.29M | 24.30M | 26.20M | 31.32M | 29.66M | 29.04M | 29.93M | 28.35M | 22.53M | 23.75M | 31.84M | 27.07M | 26.20M | 25.99M | 24.61M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | 45.78M | 31.10M | 20.76M | 35.58M | 35.95M |
| Operating Income | -35.45M | -60.45M | -82.13M | -129.53M | -139.03M | -119.61M | -115.22M |
| Net Income | -34.10M | -66.33M | -83.89M | -128.18M | -132.49M | -105.32M | -104.99M |
| Diluted EPS | - | - | -1.82 | -2.62 | -2.67 | -1.52 | -1.27 |
| R&D Expense | 48.06M | 78.44M | 94.67M | 117.84M | 117.71M | 110.64M | 104.24M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 118.26M | 400.14M | 506.76M | 430.84M | 376.45M | 349.60M | 359.07M |
| Total Equity | -79.75M | -111.96M | 280.79M | 389.61M | 289.23M | 246.11M | 215.99M | 256.59M |
| Cash & Equivalents | - | 90.55M | 181.73M | 76.12M | 29.75M | 126.59M | 55.50M | 74.60M |
| Long Term Debt | - | - | 10.05M | 10.77M | 9.20M | 0 | - | - |
| Total Liabilities | - | 119.23M | 119.35M | 117.16M | 141.61M | 130.34M | 133.62M | 102.49M |
| Current Liabilities | - | 33.64M | 43.85M | 51.25M | 44.55M | 42.77M | 45.18M | 33.03M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 55.61M | -67.25M | - | -105.94M | -106.84M | -65.16M | -98.69M |
| Investing Cash Flow | -1.62M | -190.50M | - | 58.42M | 158.35M | -51.27M | -8.60M |
| Financing Cash Flow | 244.00K | 348.93M | - | 1.15M | 45.49M | 45.34M | 126.40M |
| Capital Expenditure | -1.35M | -650.00K | - | -5.50M | -1.71M | -180.00K | -607.00K |
| Free Cash Flow | 54.27M | -67.90M | - | -111.44M | -108.55M | -65.34M | -99.30M |
| Net Change in Cash | - | - | - | -46.37M | 97.00M | -71.09M | 19.10M |
| Share Buybacks | 30.00K | 194.00K | - | 0 | 110.00K | 194.00K | 193.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -179.4% | -416.6% | -669.8% | -336.1% | -320.5% |
| Net Margin % | - | - | -183.2% | -412.2% | -638.3% | -296.0% | -292.1% |
| ROE % | 30.5% | -23.6% | -21.5% | -44.3% | -53.8% | -48.8% | -40.9% |
| ROCE % | -41.9% | -17.0% | -18.0% | -33.5% | -41.7% | -39.3% | -35.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Morgan Stanley | 7.21% | 8.87M | $30.06M |
| 2 | RA Capital Management, L.P. | 6.50% | 8.00M | $27.12M |
| 3 | Blackrock Inc. | 6.42% | 7.90M | $26.77M |
| 4 | Lynx1 Capital Management Lp | 5.96% | 7.33M | $24.84M |
| 5 | Squadron Capital Management LLC | 5.85% | 7.20M | $24.41M |
| 6 | Bain Capital Life Sciences Investors, LLC | 5.83% | 7.17M | $24.31M |
| 7 | JPMORGAN CHASE & CO | 3.86% | 4.75M | $16.09M |
| 8 | Vanguard Capital Management LLC | 3.59% | 4.42M | $14.98M |
| 9 | Citadel Advisors Llc | 3.40% | 4.19M | $14.20M |
| 10 | Goldman Sachs Group Inc | 2.87% | 3.53M | $11.97M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CCCC
C4 Therapeutics Stock Price Forecast. Should You Buy CCCC? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTFB6VHIzQkJkUXZrTlNpaGstNEdLR3BBbnVSeWVqM195QXpSZk1zUklWOVpfTDhrU3B6dDdCUmZOXzFNbkJmXy1kdg?oc=5" target="_blank">C4 Therapeutics Stock Price Forecast. Should You Buy CCCC?</a> &…
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQLWtCSFNrNUVSWmJSbndOc2RGUkU3ck1wbGlHQTZrYkNPdVdsbHNoSVBkWnpHSUdUdkliXy1nSmxjZHFab2s3ekFvaDJvLVpWOGNMMXVvUndSdnJ1SnNfdTdPNVRNa2swVjVLdnNpZlAwUEhaNW0tNG1OTXNoaXUxbWRTNVZJazhjSk9RaU…
New data detail how a blood-cancer treatment affects immune cells - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPRUdab2FfUXVNYW44eWZLN1RENnlVa01ySmFQZGUycVRrZ3oxeUVJVElteUJGcUFpZGRBbTVPbmJ6S1lOTTIyS3d3NUlPYkh4bFRnQVVGNjhURFh5QnpyekdKLU1OVUxsWElLMGc0YlV4dUVqU2lBRGFZbjREWW9xYnJjdG1zMVJBZlB6MW…
C4 Therapeutics: Priced For Perfection Ahead Of 2027 Cemsidomide Readouts (NASDAQ:CCCC) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPam1xZnN6eE1xR1Z6ZUpxRVBtd3R1SEFvdG9FNG9ZOXRoQWdleGpVSklxc18xaXlubjl5UDJfWmlxaThJcmtrcVVWTzNHTVRiYVZEN1NXc24xNm4tU3AyS1FjWlg3MkFjeHR0SVhhMWdmMU5pU2lUb3k1V1pmSzJXQlRITDlwY1FNX29JVW…
$CCCC stock is down 8% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxORHUyWkhIaTc5ZVFXVTlBSVZyOUtqejI0RlVzeEZNMldBc1I0ZFllX1Zjdk1JYkVHdnE0YlJ4cGtxYXI3Nmd4REhrS2lSZnRLUE1iZmhMaFRuSng1SmxheXNBZmxnTUkwWDBfUTh0VVFKTGlfNkp6a0lSUGZ5cUIxUm5qd1lYU1FlQy1kNF…
CCCC Stock Reverses Pre-Market Gains After Roche Tie-Up To Develop Cancer Treatments - Retail Sees Strong Upside - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxNNFhwZFByVEFDdFFBdXhiZXFsZ0FhbWFRbE5HdENvMm12d1FIZzI0MDlYdzRwVjFwTEY2ajNhZ2pwT0ZyTjR1cFEtNzQ3bERzLTdMZHpoQWM3NTUwbUUySHBtSjRGaEczWkE0WDVQVTNRV19ZeUI1RFQyU1h0NFBxQXdYbmlqSDF1ZmJ0a0…
CCCC — Frequently Asked Questions
What is the current share price of C4 Therapeutics, Inc. (CCCC)?
As of 2026-09-19 21:16 PDT, C4 Therapeutics, Inc. (CCCC) trades at $3.55 on NasdaqGS. Its 52-week range is $1.71 to $4.67.
What is the market capitalisation of CCCC?
C4 Therapeutics, Inc. (CCCC) has a market capitalisation of $436.74M on NasdaqGS.
What is the P/E ratio of CCCC?
CCCC trades at a trailing price-to-earnings (P/E) ratio of -3.90. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.71.
What is the return on equity (ROE) of CCCC?
CCCC has a return on equity (ROE) of -48.14%. Its return on capital employed (ROCE) is -35.34%.
Is CCCC a good stock to buy?
This page provides a data-driven analysis of C4 Therapeutics, Inc. (CCCC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.